Advanced search
Publication Cover
Leukemia & Lymphoma Volume 12, 1994 - Issue 3-4
Submit an article Journal homepage
28
Views
29
CrossRef citations to date
0
Altmetric
Original Article

Selective Cytotoxicity to Human Leukemic Myeloblasts Produced by Oligodeoxyribonucleotide Phosphorothioates Complementary to p53 Nucleotide Sequences

Eliel Bayever Department of Pediatrics, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA
,
Kathleen M. Haines Department of Pediatrics, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA
,
Patrick L. Iversen Department of Pharmacology, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA
,
Raymond W. Ruddon Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA
,
Samuel J. Pirruccello Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA
,
Charles P. Mountjoy Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA
,
Mark A. Arneson Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA
&
Larry J. Smith Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, 68198, USA
 show all
Pages 223-231 | Received 10 May 1993, Published online: 01 Jul 2009

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Ling Zhang, Kathy L. McGraw, David A. Sallman & Alan F. List. (2017) The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leukemia & Lymphoma 58:8, pages 1777-1790.
Read now
Mark C. Lanasa, Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, Daphne R. Friedman, Louis F. Diehl, Catherine Rehder, Harry Cook, F. Joseph Daugherty, Karen M. B. Matta, J. Brice Weinberg & David Rizzieri. (2012) Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 53:2, pages 218-224.
Read now
Umberto Galderisi, M Cipollaro & A Cascino. (2001) Clinical trials of a new class of therapeutic agents: antisense oligonucleotides. Emerging Drugs 6:1, pages 69-79.
Read now
Krzysztof Warzocha & Dariusz Wotowiec. (1997) Antisense Strategy: Biological Utility and Prospects in the Treatment of Hematological Malignancies. Leukemia & Lymphoma 24:3-4, pages 267-281.
Read now
A. Kirk Field & John Goodchild. (1995) Section Review: Biologicals & Immunologicals: Antisense oligonucleotides: Rational drug design for genetic pharmacology. Expert Opinion on Investigational Drugs 4:9, pages 799-821.
Read now

Articles from other publishers (24)

Patrick L. IversenPatrick L. Iversen. 2018. Molecular Basis of Resilience. Molecular Basis of Resilience 123 139 .
Patrick L. IversenPatrick L. Iversen. 2018. Molecular Basis of Resilience. Molecular Basis of Resilience 1 18 .
Houda Alachkar, Zhiliang Xie, Guido Marcucci & Kenneth K. Chan. (2012) Determination of cellular uptake and intracellular levels of Cenersen (Aezea®, EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells. Journal of Pharmaceutical and Biomedical Analysis 71, pages 228-232.
Crossref
Jorge Cortes, Hagop Kantarjian, Edward D. Ball, John DiPersio, Jonathan E. Kolitz, Hugo F. Fernandez, Mark Goodman, Gautam Borthakur, Maria R. Baer & Meir Wetzler. (2011) Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 118:2, pages 418-427.
Crossref
Archana Mukherjee, Eric Wickstrom & Mathew L. Thakur. (2009) Imaging oncogene expression. European Journal of Radiology 70:2, pages 265-273.
Crossref
Eric Wickstrom, Mathew L. Thakur & Edward R. Sauter. 2006. Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules. Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules 61 88 .
XIAOBING TIAN, ATIS CHAKRABARTI, NARIMAN V. AMIRKHANOV, MOHAN R. ARUVA, KAIJUN ZHANG, BOBY MATHEW, CHRISTOPHER CARDI, WENYI QIN, EDWARD R. SAUTER, MATHEW L. THAKUR & ERIC WICKSTROM. (2005) External Imaging of CCND1 , MYC , and KRAS Oncogene mRNAs with Tumor-Targeted Radionuclide-PNA-Peptide Chimeras . Annals of the New York Academy of Sciences 1059:1, pages 106-144.
Crossref
XIAOBING TIAN, MOHAN R. ARUVA, PONUGOTI S. RAO, WENYI QIN, PAUL READ, EDWARD R. SAUTER, MATHEW L. THAKUR & ERIC WICKSTROM. (2003) Imaging Oncogene Expression. Annals of the New York Academy of Sciences 1002:1, pages 165-188.
Crossref
Eric Wickstrom, Mathew L. Thakur & Edward R. Sauter. (2003) Receptor-specific targeting with complementary peptide nucleic acids conjugated to peptide analogs and radionuclides. Letters in Peptide Science 10:3-4, pages 191-214.
Crossref
Rajaraman Iyer, LieMing Ding, Ramesh B Batchu, Scott Naugler, Masood A Shammas & Nikhil C Munshi. (2003) Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Leukemia Research 27:1, pages 73-78.
Crossref
Corinne CapouladeLluis M. MirKarine CarlierYann LécluseCécile TétaudZohair MishalJoëlle Wiels. (2001) Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides. Blood 97:4, pages 1043-1049.
Crossref
Irina V. Lebedeva & C. A. Stein. (2000) Antisense Oligonucleotides in Cancer. BioDrugs 13:3, pages 195-216.
Crossref
G.H. Sakorafas, A.G. Tsiotou & G.G. Tsiotos. (2000) Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treatment Reviews 26:1, pages 29-52.
Crossref
David M. Kushner & Robert H. Silverman. (2000) Antisense cancer therapy: The state of the science. Current Oncology Reports 2:1, pages 23-30.
Crossref
W.M. Gallagher & R. Brown. (1999) p53-Oriented cancer therapies: Current progress. Annals of Oncology 10:2, pages 139-150.
Crossref
Anthony L. Boral, Scott Dessain & Bruce A. Chabner. (1998) Clinical evaluation of biologically targeted drugs: Obstacles and opportunities. Cancer Chemotherapy and Pharmacology 42:S1, pages S3-S21.
Crossref
Karl-Heinz Altmann, Doriano Fabbro & Thomas Geiger. 1998. 227 266 .
MICHAEL R. BISHOP, JOHN D. JACKSON, STEFANO R. TARANTOLO, BARBARA O'KANE-MURPHY, PATRICK L. IVERSEN, ELIEL BAYEVER, SHANTARAM M. JOSHI, J. GRAHAM SHARP, JENE L. PIERSON, PHYLLIS I. WARKENTIN, JAMES O. ARMITAGE & ANNE KESSINGER. (1997) Ex Vivo Treatment of Bone Marrow with Phosphorothioate Oligonucleotide OL(l)p53 for Autologous Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Journal of Hematotherapy 6:5, pages 441-446.
Crossref
H.K. Tewary & P.L. Iversen. (1997) Qualitative and quantitative measurements of oligonucleotides in gene therapy: Part II in vivo models. Journal of Pharmaceutical and Biomedical Analysis 15:8, pages 1127-1135.
Crossref
Yasuhide Hirota, Tadashi Horiuchi & Kouichi Akahane. (2005) p53 Antisense Oligonucleotide Inhibits Growth of Human Colon Tumor and Normal Cell Lines. Japanese Journal of Cancer Research 87:7, pages 735-742.
Crossref
Patrick L. Iversen, Bryan L. Copple & Hemant K. Tewary. (1995) Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicology Letters 82-83, pages 425-430.
Crossref
Gerald Zon. (1995) Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Molecular Neurobiology 10:2-3, pages 219-229.
Crossref
SHASHI KUMAR SRINIVASAN, HEMANT K. TEWARY & PATRICK L. IVERSEN. (1995) Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin. Antisense Research and Development 5:2, pages 131-139.
Crossref
Francesco Lanza & Sucai Bi. (2008) Role of p53 in leukemogenesis of chronic myeloid leukemia. STEM CELLS 13:4, pages 445-452.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.